These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15713827)

  • 21. High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen.
    Cao KY; Mao XP; Wang DH; Xu L; Yuan GQ; Dai SQ; Zheng BJ; Qiu SP
    Prostate; 2007 Dec; 67(16):1791-800. PubMed ID: 17929272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy.
    Uchida A; O'Keefe DS; Bacich DJ; Molloy PL; Heston WD
    Urology; 2001 Aug; 58(2 Suppl 1):132-9. PubMed ID: 11502468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
    Latham JP; Searle PF; Mautner V; James ND
    Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Transcriptional activity of WT1 gene promoter and enhancer in diverse cell lines].
    Hu SY; Chen ZX; Zhao Y; Cen JN; Gu M; Fu ZZ; He J; Gu WY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1050-5. PubMed ID: 17956689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.
    Hwang JE; Joung JY; Shin SP; Choi MK; Kim JE; Kim YH; Park WS; Lee SJ; Lee KH
    Cancer Lett; 2016 Mar; 372(1):57-64. PubMed ID: 26723876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
    Schmittgen TD; Teske S; Vessella RL; True LD; Zakrajsek BA
    Int J Cancer; 2003 Nov; 107(2):323-9. PubMed ID: 12949815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Updated application of prostate-specific membrane antigen to the diagnosis and treatment of prostate cancer].
    Tang QL; Yao MY
    Zhonghua Nan Ke Xue; 2008 Jan; 14(1):79-82. PubMed ID: 18297820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-specific expression detected with the use of an expression vector driven by human telomerase reverse transcriptase gene promoter.
    Yin J; Fu P; Wang X; Jin G; Xiu R
    J Lab Clin Med; 2004 Dec; 144(6):302-6. PubMed ID: 15614252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel prostate-specific promoter derived from PSA and PSMA enhancers.
    Lee SJ; Kim HS; Yu R; Lee K; Gardner TA; Jung C; Jeng MH; Yeung F; Cheng L; Kao C
    Mol Ther; 2002 Sep; 6(3):415-21. PubMed ID: 12231179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells.
    Cao KY; Xu L; Zhang DM; Zhang XM; Zhang T; He X; Wang Z; Feng FS; Qiu SP; Shen GX
    Int J Oncol; 2012 Jun; 40(6):1977-85. PubMed ID: 22322627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Construction and identification of a plasmid with EGFP reporter gene for enhancer function analysis].
    Shi QD; Zhang PB; Kang QY; Chen XL; Tian YM; Liu JX; Liu Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec; 27(12):1834-7. PubMed ID: 18158996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylation state of the prostate specific membrane antigen (PSMA) CpG island in prostate cancer cell lines.
    Noss KR; Singal R; Grimes SR
    Anticancer Res; 2002; 22(3):1505-11. PubMed ID: 12168830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigen.
    Lee SJ; Lee K; Yang X; Jung C; Gardner T; Kim HS; Jeng MH; Kao C
    J Mol Biol; 2003 Jul; 330(4):749-60. PubMed ID: 12850144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway.
    Guo Z; Lai Y; Du T; Zhang Y; Chen J; Bi L; Lin T; Liu H; Wang W; Xu K; Jiang C; Han J; Zhang C; Dong W; Huang J; Huang H
    Chin Med J (Engl); 2014; 127(5):929-36. PubMed ID: 24571890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1.
    Watt F; Martorana A; Brookes DE; Ho T; Kingsley E; O'Keefe DS; Russell PJ; Heston WD; Molloy PL
    Genomics; 2001 May; 73(3):243-54. PubMed ID: 11350116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor effect of dendritic cells transfected with prostate-specific membrane antigen recombinant adenovirus on prostate cancer: An in vitro study.
    Meng FD; Wang S; Jiang YH; Sui CG
    Mol Med Rep; 2016 Mar; 13(3):2124-34. PubMed ID: 26783185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.
    Ghosh A; Heston WD
    J Cell Biochem; 2004 Feb; 91(3):528-39. PubMed ID: 14755683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
    Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
    Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promoter analysis of human glutamate carboxypeptidase II.
    Han L; Wong DL; Tsai G; Jiang Z; Coyle JT
    Brain Res; 2007 Sep; 1170():1-12. PubMed ID: 17689503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.